×
ADVERTISEMENT

AstraZeneca/MedImmune

FDA Approves Lumoxiti for Hairy Cell Leukemia

Lumoxiti is a CD22-directed cytotoxin approved to treat adults with relapsed or refractory hairy cell leukemia.

SEPTEMBER 13, 2018

FDA Approves Fasenra for Severe Eosinophilic Asthma

The FDA approved benralizumab for the add-on maintenance treatment of patients with severe eosinophilic phenotype ...

NOVEMBER 15, 2017

Load more